The Relative Strength (RS) Rating for Vericel (VCEL) stock entered a higher percentile Monday, as it got a lift from 69 to 79.
↑ XIBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Vericel stock can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vericel stock broke out on Nov. 7 and has moved more than 5% past a 50.00 entry in a first-stage double bottom, meaning it's extended and now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The biotech company reported 0% EPS growth in its most recent report, while sales growth came in at 27%.
Vericel stock earns the No. 45 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。